Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome

NCT02063659 is registered in ClinicalTrials.gov with Lexicon Pharmaceuticals as lead sponsor.

NCT NCT02063659
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02063659 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome
Lead sponsor
Lexicon Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
March 11, 2014
Completion date
March 29, 2016
Enrollment
76 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoid syndrome